Literature DB >> 28247421

Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.

Devendra K Hiwase1,2,3,4, Deepak Singhal1,2,3, Corinna Strupp5, Rakchha Chhetri1, Monika M Kutyna1, L Amilia Wee1, Peter B Harrison1, Shriram V Nath6, Nicholas Wickham7, Chi-Hung Hui7, James X Gray8, Peter Bardy1,2,3, David M Ross1,2,3,9, Ian D Lewis1,2,3, John Reynolds10, L Bik To1,2,3, Ulrich Germing5.   

Abstract

RBC-transfusion dependency (RBC-TD) is an independent prognostic factor for poor overall survival (OS) in the WHO classification-based prognostic scoring system (WPSS) for MDS patients. However, WPSS did not include cytopenia, whereas revised International Prognostic Scoring System (IPSS-R) did not include RBC-TD. Thus, neither of these prognostic scoring systems incorporates both cytopenia and RBC-TD. We aimed to test whether RBC-TD adds prognostic value to the IPSS-R. We analyzed MDS patients not treated with disease-modifying therapy, and enrolled in SA-MDS Registry (derivation cohort; n = 295) and Dusseldorf registry (Germany; validation cohort; n = 113) using time-dependent Cox proportional regression and serial landmark analyses. In the derivation cohort, RBC-TD patients had inferior OS compared to RBC transfusion-independent (RBC-TI) patients (P < 0.0001) at 6- (18 vs. 64 months), 12- (24 vs. 71 months), and 24-months (40 vs. 87 months). In a Cox proportional regression analysis, RBC-TD was an independent adverse prognostic marker in addition to age, sex, and IPSS-R variables (P < 0.0001). A prognostic index (PI) was derived using these Cox-proportional regression model variables. In the validation cohort, this PI classified patients into four prognostic groups with significantly different OS (P < 0.001) as in the derivation cohort. In conclusion, multivariate analysis by Cox proportional hazards regression and serial landmark analyses clearly demonstrates that development of RBC-TD at any time during the course of MDS is associated with poor OS, independent of IPSS-R. This study demonstrates that dynamic assessment of RBC-TD provides additional prognostic value to IPSS-R and should be included in treatment decision algorithms for MDS patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28247421     DOI: 10.1002/ajh.24704

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  Lower risk but high risk.

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).

Authors:  Annika Kasprzak; Kathrin Nachtkamp; Norbert Gattermann; Ulrich Germing
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

3.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Authors:  Hamish S Scott; Christopher N Hahn; Devendra K Hiwase; Deepak Singhal; Li Yan A Wee; Monika M Kutyna; Rakchha Chhetri; Joel Geoghegan; Andreas W Schreiber; Jinghua Feng; Paul P-S Wang; Milena Babic; Wendy T Parker; Smita Hiwase; Suzanne Edwards; Sarah Moore; Susan Branford; Teodora Kuzmanovic; Nimit Singhal; Raghu Gowda; Anna L Brown; Peer Arts; Luen B To; Peter G Bardy; Ian D Lewis; Richard J D'Andrea; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2019-05-14       Impact factor: 11.528

Review 4.  Myelodysplastic syndromes current treatment algorithm 2018.

Authors:  David P Steensma
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

5.  Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study.

Authors:  P Joy Ho; Devendra Hiwase; Raj Ramakrishna; Nicholas Viiala; Ann Solterbeck; Robert Traficante; Evren Zor; Othon L Gervasio; Laura M High; David M Ross; Donald K Bowden
Journal:  Hemasphere       Date:  2019-06-04

6.  Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

Authors:  Louise de Swart; Simon Crouch; Marlijn Hoeks; Alex Smith; Saskia Langemeijer; Pierre Fenaux; Argiris Symeonidis; Jaroslav Cermâk; Eva Hellström-Lindberg; Reinhard Stauder; Guillermo Sanz; Moshe Mittelman; Mette Skov Holm; Luca Malcovati; Krzysztof Mądry; Ulrich Germing; Aurelia Tatic; Aleksandar Savic; Antonio Medina Almeida; Njetocka Gredelj-Simec; Agnes Guerci-Bresler; Odile Beyne-Rauzy; Dominic Culligan; Ioannis Kotsianidis; Raphael Itzykson; Corine van Marrewijk; Nicole Blijlevens; David Bowen; Theo de Witte
Journal:  Haematologica       Date:  2019-06-06       Impact factor: 9.941

7.  Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.

Authors:  Deepak Singhal; Monika M Kutyna; Rakchha Chhetri; Li Yan A Wee; Sophia Hague; Lakshmi Nath; Shriram V Nath; Romi Sinha; Nicholas Wickham; Ian D Lewis; David M Ross; Peter G Bardy; Luen Bik To; John Reynolds; Erica M Wood; David J Roxby; Devendra K Hiwase
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941

Review 8.  Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.

Authors:  Ulrich Germing; Ester N Oliva; Devendra Hiwase; Antonio Almeida
Journal:  Hemasphere       Date:  2019-10-30

9.  Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.

Authors:  Judith Strapatsas; Elena Calina Barbulescu; Michael Lauseker; Jennifer Kaivers; Barbara Hildebrandt; Kathrin Nachtkamp; Corinna Strupp; Martina Rudelius; Rainer Haas; Ulrich Germing
Journal:  Ann Hematol       Date:  2021-07-29       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.